Venetoclax
This targeted oral therapy works by blocking BCL-2, a protein that prevents cancer cells from dying, and is used to treat certain types of leukemia (particularly chronic lymphocytic leukemia and acute myeloid leukemia) when combined with other medications. A potentially serious side effect called tumor lysis syndrome can occur at the start of treatment as cancer cells die rapidly, so the dose is gradually increased and patients require careful monitoring and hydration. It is a significant advance for blood cancers that overexpress BCL-2.
Molekularmasse
868,4000 g/mol
LogP
8,20
TPSA
183,00 Ų
Lipinski-Regel der Fünf
Nicht bestanden
Therapeutische Bereiche
Pharmacokinetics (PK)
Pharmacodynamics (PD)
2D-Struktur
Cite this structure
Embed this structure
SMILES
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
InChI
InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)
Molecular Formula
C45H50ClN7O7S
HBD / HBA
3 / 11
Rotierbare Bindungen
12
Schwere Atome
61
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This targeted oral therapy works by blocking BCL-2, a protein that prevents cancer cells from dying, and is used to treat certain types of leukemia (particularly chronic lymphocytic leukemia and acute myeloid leukemia) when combined with other medications. A potentially serious side effect called tumor lysis syndrome can occur at the start of treatment as cancer cells die rapidly, so the dose is gradually increased and patients require careful monitoring and hydration. It is a significant advance for blood cancers …
Yes, Venetoclax is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3137309. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 49846579. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="venetoclax"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/venetoclax/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/venetoclax/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/venetoclax/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="venetoclax"></drugfyi-drug>